Welcome to our dedicated page for OptimizeRx SEC filings (Ticker: OPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OptimizeRx Corporation filings document the public-company records of a Nevada healthcare technology issuer serving life sciences companies through HCP and patient engagement platforms. Its SEC disclosures include material-event reports on operating results, financing agreement amendments, share repurchase authorization, executive and board appointments, auditor changes, and related internal-control matters.
OptimizeRx proxy materials cover director elections, advisory executive compensation votes, equity incentive plan amendments, and auditor ratification. The filings also provide formal governance records for board composition, committee service, compensation arrangements, capital-structure actions, and risk-related disclosures tied to the company’s digital healthcare marketing operations.
OptimizeRx Corporation (OPRX) filed an 8-K on June 24, 2025 to disclose a governance change. Effective June 20, 2025, the Board of Directors expanded from five to six members and appointed CEO Stephen Silvestro to fill the new seat. Silvestro will serve until the 2026 annual meeting, subject to earlier resignation or removal. No other executive departures, financial data, or strategic transactions were reported. The company furnished a related press release as Exhibit 99.1; the information in Item 7.01 is deemed “furnished,” not “filed,” under the Exchange Act.
Aside from this board adjustment, the 8-K contains no updates on earnings, guidance, or operations. Therefore, the filing is primarily informational and unlikely to have a material impact on valuation or near-term cash flows.